A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs

Trial Identifier: D5551R00015
Sponsor: AstraZeneca
Collaborator:
IQVIA Ltd
Start Date: September 2024
Primary Completion Date: March 2026
Study Completion Date: March 2026
Condition: Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Denmark Copenhagen, Denmark
England London, England
Finland Helsinki, Finland
France Paris, France
Norway Bergen, Norway
Scotland Edinburgh, Scotland
Spain Barcelona, Spain
Sweden Vänersborg, Sweden